Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression

EMBO Molecular Medicine

Volumn 7, Issue 7, 2015, Pages 950-972

  Centritto, Floriana ^a   Paroni, Gabriela ^a   Bolis, Marco ^a   Garattini, Silvio Ken ^a   Kurosaki, Mami ^a   Barzago, Maria Monica ^a   Zanetti, Adriana ^a   Fisher, James Neil ^a   Scott, Mark Francis ^a   Pattini, Linda ^b   Lupi, Monica ^a   Ubezio, Paolo ^a   Piccotti, Francesca ^c   Zambelli, Alberto ^d   Rizzo, Paola ^a   Gianni', Maurizio ^a   Fratelli, Maddalena ^a   Terao, Mineko ^a   Garattini, Enrico ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c IRCCS   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Breast cancer; Luminal phenotype; Nuclear receptor; RARalpha; Retinoic acid

Indexed keywords

ANTINEOPLASTIC AGENT; RARA PROTEIN, HUMAN; RARA PROTEIN, MOUSE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

ANIMAL; BIOSYNTHESIS; BREAST TUMOR; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMANS; RECEPTORS, RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN;

EID: 84934442148     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404670     Document Type: Article

References (61)

1. Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Zhang Y, Hill J, Bissonnette RP, Medina D, Brown PH et al. (2008) Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med Genomics 1: 40
2. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R et al. (2015) Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21: 396-404
3. Alvarez R, Vaz B, Gronemeyer H, de Lera AR (2014) Functions, therapeutic applications, and synthesis of retinoids and carotenoids. Chem Rev 114: 1-125
4. Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Recher C, Dusanter-Fourt I et al. (2013) CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget 4: 1438-1448
5. Balmer JE, Blomhoff R (2002) Gene expression regulation by retinoic acid. J Lipid Res 43: 1773-1808
6. Balmer JE, Blomhoff R (2005) A robust characterization of retinoic acid response elements based on a comparison of sites in three species. J Steroid Biochem Mol Biol 96: 347-354
7. Belosay A, Brodie AM, Njar VC (2006) Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res 66: 11485-11493
8. Berry DC, Noy N (2007) Is PPARbeta/delta a retinoid receptor? PPAR Res 2007: 73256
9. Bosch A, Bertran SP, Lu Y, Garcia A, Jones AM, Dawson MI, Farias EF (2012) Reversal by RARalpha agonist Am580 of c-Myc-induced imbalance in RARalpha/RARgamma expression during MMTV-Myc tumorigenesis. Breast Cancer Res 14: R121
10. Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954
11. Connolly RM, Nguyen NK, Sukumar S (2013) Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 19: 1651-1659
12. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M et al. (2013) Modeling precision treatment of breast cancer. Genome Biol 14: R110
13. Di Lorenzo D, Gianni M, Savoldi GF, Ferrari F, Albertini A, Garattini E (1993) Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells. Biochem Biophys Res Commun 192: 1066-1072
14. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M et al. (2013) PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA 110: 21124-21129
15. Ekici M, Hohl M, Schuit F, Martinez-Serrano A, Thiel G (2008) Transcription of genes encoding synaptic vesicle proteins in human neural stem cells: chromatin accessibility, histone methylation pattern, and the essential role of rest. J Biol Chem 283: 9257-9268
16. Errico A (2014) Breast cancer: RARRES3-suppressing metastases to the lung in breast cancer. Nat Rev Clin Oncol 11: 378
17. Garattini E, Gianni M, Terao M (2007a) Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm 75: 301-354
18. Garattini E, Gianni M, Terao M (2007b) Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 13: 1375-1400
19. Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, Gianni M, Zanetti A, Pagani A, Fisher JN et al. (2014) Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev 40: 739-749
20. Gianni M, Zanotta S, Terao M, Garattini S, Garattini E (1993) Effects of synthetic retinoids and retinoic acid isomers on the expression of alkaline phosphatase in F9 teratocarcinoma cells. Biochem Biophys Res Commun 196: 252-259
21. Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, Rambaldi A, Garattini E (1996) AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 87: 1520-1531
22. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, Barbui T, Rambaldi A, Garattini E (1997) Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 89: 1001-1012
23. Gianni M, Peviani M, Bruck N, Rambaldi A, Borleri G, Terao M, Kurosaki M, Paroni G, Rochette-Egly C, Garattini E (2012) p38alphaMAPK interacts with and inhibits RARalpha: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells. Leukemia 26: 1850-1861
24. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M et al. (2012) A refined molecular taxonomy of breast cancer. Oncogene 31: 1196-1206
25. Hua S, Kittler R, White KP (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137: 1259-1271
26. Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, Hultin-Rosenberg L, Lundgren B, Martens U, Mathe G et al. (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 4: 2175
27. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N (2010) Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem 285: 19106-19115
28. Kikuchi K, Tagami K, Hibi S, Yoshimura H, Tokuhara N, Tai K, Hida T, Yamauchi T, Nagai M (2001) Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor alpha antagonists. Bioorg Med Chem Lett 11: 1215-1218
29. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW et al. (2006) Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66: 12009-12018
30. Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lonning PE, Lillehaug JR, Pendino F (2011) RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Ann Oncol 22: 2208-2215
31. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH (2005) The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65: 3462-3469
32. van der Kuip H, Murdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE (2006) Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 6: 86
33. Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, Wesley RA et al. (2011) An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest 121: 880-892
34. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E et al. (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369: 111-121
35. Maitra U, Parks JS, Li L (2009) An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol Cell Biol 29: 5989-5997
36. Mark M, Ghyselinck NB, Chambon P (2009) Function of retinoic acid receptors during embryonic development. Nucl Recept Signal 7: e002
37. Montero JC, Seoane S, Ocana A, Pandiella A (2011) P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 30: 1059-1071
38. Montero JC, Seoane S, Pandiella A (2013) Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal 25: 2281-2289
39. Morales M, Arenas EJ, Urosevic J, Guiu M, Fernandez E, Planet E, Fenwick RB, Fernandez-Ruiz S, Salvatella X, Reverter D et al. (2014) RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol Med 6: 865-881
40. Noy N (2010) Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr 30: 201-217
41. Nwankwo JO (2002) Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)-catechin in Dunning rat invasive prostate adenocarcinoma cells. Anticancer Res 22: 4129-4135
42. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167
43. Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M et al. (2012) Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 31: 3431-3443
44. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129: 723-733
45. Shaw N, Elholm M, Noy N (2003) Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem 278: 41589-41592
46. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
47. Somenzi G, Sala G, Rossetti S, Ren M, Ghidoni R, Sacchi N (2007) Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLoS ONE 2: e836
48. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423
49. Szondy Z, Reichert U, Bernardon JM, Michel S, Toth R, Ancian P, Ajzner E, Fesus L (1997) Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol Pharmacol 51: 972-982
50. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM et al. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028
51. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ et al. (2011) Induction of miR-21 by retinoic acid in estrogen-receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem 286: 4027-4042
52. Thatcher JE, Zelter A, Isoherranen N (2010) The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 80: 903-912
53. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567-6572
54. Topletz AR, Thatcher JE, Zelter A, Lutz JD, Tay S, Nelson WL, Isoherranen N (2012) Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases. Biochem Pharmacol 83: 149-163
55. Topletz AR, Tripathy S, Foti RS, Shimshoni JA, Nelson WL, Isoherranen N (2015) Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Mol Pharmacol 87: 430-441
56. Uray IP, Brown PH (2011) Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 188: 147-162
57. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116
58. Voigt W (2005) Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110: 39-48
59. Wright PK, May FE, Darby S, Saif R, Lennard TW, Westley BR (2009) Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int J Clin Exp Pathol 2: 463-475
60. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R et al. (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen-receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376-6380
61. Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG (2013) Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2: 233-242